Pharmacokinetics of acenocoumarol in patients with Bjork valvular prothesis

M. Arboix; E. Rey; F. Clos; J. Camarasa

Pharmacokinetics of acenocoumarol in patients with Bjork valvular prothesis

M. Arboix, E. Rey, F. Clos, J. Camarasa

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Acenocoumarol is an oral anticoagulant of the coumarin group which has not been precisely characterized with respect to its kinetic behaviour after oral administration. This study was conducted in 10 patients with valvular prosthesis and on long-term acenocoumarol therapy. In those who were administered an oral dose of 0.11 ± 0.01 mg/kg, it was observed that acenocoumarol presents a slow and erratic absorption, reaching maximum concentration between one and three hours after administration. The plasma elimination half-life of approximately six hours is shorter than that of other coumarins widely used in the clinic, such as warfarin or phenprocoumon.

Original language	English
Pages (from-to)	33-36
Journal	Revista de Farmacologia Clinica y Experimental
Volume	2
Issue number	1
Publication status	Published - 1 Jan 1985

Cite this

@article{049ef3c215bb4be4965f4bae904f6452,

title = "Pharmacokinetics of acenocoumarol in patients with Bjork valvular prothesis",

abstract = "Acenocoumarol is an oral anticoagulant of the coumarin group which has not been precisely characterized with respect to its kinetic behaviour after oral administration. This study was conducted in 10 patients with valvular prosthesis and on long-term acenocoumarol therapy. In those who were administered an oral dose of 0.11 ± 0.01 mg/kg, it was observed that acenocoumarol presents a slow and erratic absorption, reaching maximum concentration between one and three hours after administration. The plasma elimination half-life of approximately six hours is shorter than that of other coumarins widely used in the clinic, such as warfarin or phenprocoumon.",

author = "M. Arboix and E. Rey and F. Clos and J. Camarasa",

year = "1985",

month = jan,

day = "1",

language = "English",

volume = "2",

pages = "33--36",

number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of acenocoumarol in patients with Bjork valvular prothesis

AU - Arboix, M.

AU - Rey, E.

AU - Clos, F.

AU - Camarasa, J.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Acenocoumarol is an oral anticoagulant of the coumarin group which has not been precisely characterized with respect to its kinetic behaviour after oral administration. This study was conducted in 10 patients with valvular prosthesis and on long-term acenocoumarol therapy. In those who were administered an oral dose of 0.11 ± 0.01 mg/kg, it was observed that acenocoumarol presents a slow and erratic absorption, reaching maximum concentration between one and three hours after administration. The plasma elimination half-life of approximately six hours is shorter than that of other coumarins widely used in the clinic, such as warfarin or phenprocoumon.

AB - Acenocoumarol is an oral anticoagulant of the coumarin group which has not been precisely characterized with respect to its kinetic behaviour after oral administration. This study was conducted in 10 patients with valvular prosthesis and on long-term acenocoumarol therapy. In those who were administered an oral dose of 0.11 ± 0.01 mg/kg, it was observed that acenocoumarol presents a slow and erratic absorption, reaching maximum concentration between one and three hours after administration. The plasma elimination half-life of approximately six hours is shorter than that of other coumarins widely used in the clinic, such as warfarin or phenprocoumon.

M3 - Article

VL - 2

SP - 33

EP - 36

IS - 1

ER -

Pharmacokinetics of acenocoumarol in patients with Bjork valvular prothesis

Abstract

Fingerprint

Cite this